

Our contribution to the Sustainable Development Goals

In 2018, we set out [13 public commitments](#) that together reflect the breadth of our contribution towards addressing the UN's Global Goals for Sustainable Development while delivering sustainable, improved financial returns for our shareholders. We report progress against these commitments each year in our Annual Report.



As a science-led healthcare company **Goal 3, Good Health & Wellbeing**, is where we can make the most important contribution. The goal is underpinned by targets that cover a wide range of health issues from maternal and child health, to TB, malaria, HIV and environmental health.

Although each of the 17 global goals is focused on a different issue, we believe that health underpins almost every development theme, each of which enables, or is enabled by, advances in population health.

How we support SDG 3

The primary way in which we support SDG 3 is by using our science and technology to address health needs, and by making our products affordable and available.

Using our science and technology to address health needs

The biggest impact that we can have on health is to successfully research and develop innovative products. Through our innovation we aim to develop differentiated, high quality, needed medicines, vaccines and consumer products to improve health.

We also have a responsibility to impact global health, particularly in the prevention and treatment of infectious diseases where we have world-leading scientific expertise. We support global efforts to reduce the burden of HIV/AIDS, TB, malaria and neglected tropical diseases (NTDs), which disproportionately affect people in developing countries, through a range of R&D initiatives. In 2018, GSK topped the Access to Medicines Index for the sixth consecutive time, with specific recognition for having the largest proportion of our R&D pipeline dedicated to priority diseases.

This work supports **SDG 3.3¹** and **3.B²** in particular. Examples in this area include:

- **HIV:** Through ViiV Healthcare, we are progressing clinical development programmes for paediatric formulations of our HIV medicines in partnership with the International Maternal Paediatric Adolescent AIDS Clinical Trials Network and the Paediatric European Network for Treatment of AIDS.
- **TB:** We have been working with non-profit scientific organisation Aeras, and with the support of the Bill & Melinda Gates Foundation, the UK's Department for International Development and others, to develop a candidate TB vaccine. We received positive interim results in 2018 for the phase IIb study, and are continuing the trial with the International AIDS Vaccine Initiative which has recently acquired the TB vaccine clinical programme from Aeras. We also have a number of promising TB medicines in development.
- **Malaria:** Our new malaria treatment tafenoquine (*Krintafel/Kozenis*) is a single dose radical cure for *P. vivax* malaria, developed in partnership with the Medicines for Malaria Venture (MMV) and the first new treatment for this type of relapsing malaria in over 60 years. Our malaria vaccine RTS,S (*Mosquirix*), which aims to protect children from *P. falciparum* malaria, responsible for most malarial deaths worldwide, is moving into a World Health Organisation (WHO)-led pilot implementation programme in Ghana, Kenya and Malawi. We also have clinical trials underway for a next-generation malaria vaccine.
- **NTDs:** At our Tres Cantos Open Lab and Vaccines Global Health Institute our scientists research NTDs such as Chagas disease, leishmaniasis, sleeping sickness and enteric infections. Through our Tres Cantos Open Lab

¹ **Target 3.3:** By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases

² **Target 3.b:** Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all

Foundation – an independent charity – visiting scientists can also work on their own projects to target diseases disproportionately affecting the developing world, while accessing GSK’s expertise, resources and capabilities.

In support of **SDG 3.D**³ we are using our vaccines, medicines and scientific know-how to help the world to better prepare for future disease outbreaks with pandemic potential and tackle antimicrobial resistance (AMR).

- To prepare for future public health emergencies, we continue to advance rapid-response vaccine platform technologies and we are collaborating on the development of a universal influenza vaccine candidate.
- We ranked first among the large pharmaceutical companies in the Access to Medicine Foundation’s AMR Benchmark in 2018 and are committed to researching and developing new vaccines against infections that will reduce the need for antibiotics even further. For example, we are currently developing vaccines against RSV (a virus) as well as shigellosis and TB (both caused by bacteria) which are all drivers of current antibiotic use, and gepotidacin, in our Pharmaceuticals pipeline is potentially the first in a new class of antibiotics.

Making our products affordable and available

We aim to improve the health of millions of people each year by making our products available at responsible prices that are sustainable for our business. In developing countries, we use innovative pricing structures as part of our access strategies to extend product reach and in developed markets, we apply a value-based approach to balance reward for innovation with access and affordability.

We also work in partnership with NGOs, donor organisations, governments and the WHO to broaden access to medicines, vaccines and other important health interventions in developing countries.

This work supports **SDG 3.8**⁴ and **3.C**⁵ in particular. Examples in this area include:

- **Access to vaccines:** GSK has one of the most diverse vaccines portfolios in the industry, ranging from traditional childhood vaccines to newer vaccines with few other suppliers. We reserve our lowest vaccines prices for organisations such as Gavi, the Vaccine Alliance, delivering them millions of doses each year.
- **Access to HIV medications:** ViiV Healthcare’s voluntary licences enable generic manufacturers to sell its HIV products to donor agencies and public-sector programmes at a significantly reduced price.
- **Access to NTD treatment:** We have committed to donate approximately 600 million albendazole treatments to WHO each year until lymphatic filariasis (LF) is eliminated as a public health problem globally (8.5 billion donated over the last two decades). We have also committed to donate up to 400 million albendazole treatments to WHO through to the end of 2020 for deworming programmes for school aged children.
- **Save the Children partnership interventions:** Our ten-year, multi-faceted partnership with Save the Children to help reduce the number of children dying from preventable and treatable diseases has reached millions of children under five since 2013, in over 45 countries, with interventions including widening immunisation coverage, accelerating access to treatments and strengthening healthcare systems. It has also supported the development and delivery of *Umbipro*, our chlorhexidine gel to prevent umbilical cord infections.
- **Training frontline health workers:** We have a longstanding investment in training frontline health workers in developing countries, in partnership with Amref Health Africa, CARE International and Save the Children.

³ **Target 3.d:** Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks

⁴ **Target 3.8:** Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all

⁵ **Target 3.c:** Substantially increase health financing and the recruitment, development, training and retention of the health workforce in developing countries, especially in least developed countries and small island developing States

GSK contributes to a number of the SDGs beyond SDG 3. Here we outline some key examples of our work that further supports the development goals:



Goal 1: No Poverty

As a global healthcare company, our biggest contribution to support those in vulnerable situations such as humanitarian disasters, is through product donations of our medicines and vaccines, distributed by our partners.



Goal 5: Gender Equality

We aim for over 37% female representation in our senior roles by 2022. We have a programme to support development and career progression for high-performing female managers, recruit and support women early in their careers and report progress on the proportion of women in SVP/VP and management level roles. Our female senior executive population is increasing as long-running programmes to create a strong female pipeline deliver results.



Goal 6: Water & Sanitation

We have robust controls in place to manage the risk of pharmaceuticals – and particularly antibiotics – entering the environment through our waste water pollution and we work with supply chain partners to audit compliance and share best practice across our industry on managing environmental discharges. We audit our sites looking for ways to reduce our water usage and aim to cut total water use at each site with high water risk areas by 30% by 2030.



Goal 8: Decent Work & Economic Growth

In support of employee health and wellbeing, we have a comprehensive preventive healthcare package for employees – and their eligible dependents – in every country where we operate. We have placed a strong focus on improving the effectiveness of our people managers and ensuring most employees have development plans in place.



Goal 9: Industry, Innovation & Infrastructure

See how we support Goal 3 above for details on our work to research and develop innovative healthcare products.



Goal 10: Reduced inequalities

We have global disability, gender, ethnicity and LGBT+ councils which drive our diversity agenda with support from our employee resource groups. We have pledged support for the UN LGBTI global business standards and signed the Charter for Change at the 2018 UK Government Department for International Development Global Disability Summit to ensure rights, freedoms, dignity and inclusion for people with disabilities.



Goal 12: Responsible Consumption & Production

Our goal is for all our waste to be repurposed for beneficial uses by 2030, avoiding harmful environmental impacts from landfill and keeping materials in circulation for use in new products. We have initiatives in place to reduce plastic use, increase use of recycled plastic content and encourage the recycling of plastic components. We are targeting 60% of our electricity to come from renewable sources by 2030.



Goal 13: Climate Action

By 2030 we aim to reduce our operational carbon emissions (Scope 1 and 2) by 20% and reduce our value chain carbon emissions (Scope 3) by 25% per £ billion revenue. Scope 1 and 2 emissions are being reduced through ongoing efficiency measures, investment in on-site generation of renewable energy and a reduction in the number of sites. Our supply chain makes up the largest share (45%) of our Scope 3 value chain carbon footprint and we run 'kaizen' events to improve energy efficiency and recognise achievements through our Supplier Environmental Sustainability Awards.



Goal 15: Life on Land

We are committed to moving towards deforestation-free sourcing for all key commodities purchased directly by GSK or indirectly on our behalf, although we recognise this is a challenge due to the complex nature of our supply chains. To date, we have focused on paper packaging, palm oil and palm oil derivatives and have developed supplier selection criteria, as well as sourcing standards in conjunction with the Rainforest Alliance.



Goal 16: Peace, Justice & Strong Institutions

We are committed to upholding the Universal Declaration of Human Rights and the core labour standards set out by the International Labour Organization. We have assessed our human rights risks to ensure we are focusing efforts where our business has the greatest potential to impact people. Every employee and complementary worker is required to complete mandatory annual training on our Code of Conduct. We have a zero-tolerance approach to bribery and corruption and a robust enterprise-wide anti-bribery and corruption (ABAC) programme designed to respond to associated risks. We have a Third-Party Oversight programme to strengthen our management of risk in the supply chain by driving improvements in our network of third parties.



Goal 17: Partnerships for the Goals

In our R&D organisation we form diverse partnerships across academia, charitable institutions and tech companies, in pursuit of ground-breaking innovation. Our global health work in support of SDG3 has been done in partnership with many organisations such as PATH, MMV and others. We worked with the Rainforest Alliance to establish a sourcing standard for paper packaging, based on the principles of the Forest Stewardship Council. We believe partnerships across companies, funders, governments and development NGOs spread risks and draw on each parties' unique expertise, offering the best route for global health discoveries to be incentivised, developed and brought to patients as rapidly as possible.